Tobias, native of Switzerland, spent most of his formative years in Basel. Favorite activities there include tennis, Fasnacht, and swimming in the Rhine on hot summer days. At the age of 18, he moved permanently to the US in 1990 to attend Duke University. After undergraduate research stints at the Biocenter (with Jeff Schatz) and the Whitehead institute (with Harvey Lodish), Tobias moved to New York in 1993 to enroll in the Tri-Institutional MD-PhD Program. As graduate student, Tobias studied the mechanisms of SNARE complex formation and disassembly in Jim Rothman’s lab and explored the potential of genetically encoded reporters of biological function under Gero Miesenböck. Tobias went on to train in internal medicine and infectious diseases and joined Eric Pamer’s lab for post-doctoral studies in fungal pathogenesis and immunology. In 2009, Tobias started his own laboratory-based research program at Fred Hutchinson Cancer Research Center with a focus on human fungal pathogens, antifungal immunity, and, more recently, on the mycobiota and antifungal drug resistance. He relocated to Memorial Sloan Kettering in 2013 where he is now the Chief of the Infectious Disease Service. Outside the lab, Tobias loves to explore New York on foot, play board games with his kids, listen to Lana Del Rey and NPR, and head to the Western Catskills to swim, lounge, and enjoy nature.
My Pages
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Tobias Hohl discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.
View all disclosures